Day: April 5, 2022

OSLO, Norway (5 April 2022) – TGS, a global provider of energy data and intelligence, today announced the start of a new 3D reprocessing project offshore Malaysia, the first stage of which will cover a 16,957 square kilometer area, integrating existing 3D seismic data offshore Peninsular Malaysia. Thirty-six 3D seismic surveys of varying vintages covering a key part of the Malay Basin will be processed through a high-end comprehensive broadband workflow by TGS’ consortium partner DownUnder GeoSolutions (DUG) in their Kuala Lumpur processing center. The workflow, which includes FWI, Q-Migration, and Q-Tomo, will create a single contiguous 3D volume and represents the only way oil and gas companies can access a modern regional scale dataset to evaluate the Malay Basin. This new dataset will allow for improved play mapping and...

         Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles Long-term safety profile of VYVGART treatment consistent with Phase 3 ADAPT study VYVGART is the first-and-only approved neonatal Fc receptor (FcRn) blocker Breda, the Netherlands—April 5, 2022—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART® (efgartigimod alfa-fcab) for the treatment of adults with gMG. The data will be presented today in an oral presentation at the 74th Annual...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. CALGARY, Alberta., April 05, 2022 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware”) (TSXV: AXE), a Canadian clean-tech innovator of radio frequency (RF) heating technologies today announced that it has closed its second non-brokered private placement of 10% unsecured convertible debentures due 2026 (the “Debentures”), for gross proceeds of $715,000 (the “Private Placement”). Details of the Private Placement Each Debenture matures four years after the issue date and is convertible into units of Acceleware at a conversion price of $0.80. If Acceleware subsequently sells common shares (or securities that are convertible into or exchangeable for common shares) at a lower purchase (or conversion) price, the conversion price of the Debentures will be adjusted...

Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma®Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma, as well as produce gene therapy product for current and future clinical trials. The clearance of this milestone brings online the second commercially-licensed manufacturing facility for Novartis Gene Therapies, joining the Libertyville, Ill. site, which was approved for Zolgensma® (onasemnogene abeparvovec) manufacturing and distribution in 2019. The Durham site will build on Novartis Gene Therapies’...

Enters into Cooperation Agreement with Indaba Capital Management CHARLESTON, S.C., April 04, 2022 (GLOBE NEWSWIRE) — Benefitfocus, Inc. (NASDAQ: BNFT) (“Benefitfocus” or the “Company”), today announced that it has entered into a cooperation agreement with Indaba Capital Management, L.P. (“Indaba”), which owns approximately 11.8% of the Company’s outstanding shares, making it one of the Company’s largest common stockholders. Under the terms of the agreement, Benefitfocus has appointed Alexander Lerner, Investment Partner at Indaba, to the Board of Directors, effective immediately, and agreed to include Mr. Lerner on its recommended slate of nominees for election at the Company’s 2022 Annual Meeting of Stockholders. Mr. Lerner will serve as Co-Chair of each of the Board’s Nominating and Governance committee and Strategy and...